Bellevue Group AG

ZURICH, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$4.82B2026 Q3
Positions154
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.47.1%

Bellevue Group AG reported 154 positions worth $4.82B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: AMGN (7.5%). Biggest move: add BIIB ($135.0M).

10 / 154 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 AMGNAmgen$363.2M7.54%861,690——+9.7%
▸ 2 GILDGilead Sciences$320.6M6.65%2,150,692——+12.4%
▸ 3 VRTXVertex Pharmaceuticals Inc$302.5M6.28%578,532——+2.9%
▸ 4 ARGXArgenx$278.6M5.78%290,507——-0.8%
▸ 5 REGNRegeneron Pharmaceuticals$212.0M4.40%279,590——+25.6%
▸ 6 RVMDRevolution Medicines$205.0M4.25%998,950——-18.7%
▸ 7 INSMInsmed$172.1M3.57%1,508,034——+7.7%
▸ 8 VRDNViridian Therapeutics$146.4M3.04%7,109,318——+49.9%
▸ 9 ORKAOruka Therapeutics$136.7M2.84%1,641,059——+19.1%
▸ 10 BIIBBiogen$135.1M2.80%597,924——+11.4%

Pro Feature

The remaining 144 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Bellevue Group AG hold as of Q3 2026?

Bellevue Group AG reported 154 positions worth $4.82B in its Q3 2026 13F filing. Largest positions: AMGN (7.5%), GILD (6.7%), VRTX (6.3%), ARGX (5.8%) and REGN (4.4%).

What did Bellevue Group AG buy in Q3 2026?

New positions: KOD, DMRA, ANRO, LBRX and EPRX (24 in all). Added to: BIIB, REGN, INCY, ALNY and AXSM (41 in all).

What did Bellevue Group AG sell in Q3 2026?

Reduced: VERA, IONS, SYK, UNH and IMCR (67 in all). Sold out entirely: NUVLEUR, CRNXGBP, RARE, CLDX and DAMORA THERAPEUTICS INC (18 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.